Continuous Deep Sedation Viable for Advanced Cancer Patients in Palliative Setting

Share this content:
Continuous deep sedation should be considered a viable option for patients with advanced cancer being cared for in a palliative setting.
Continuous deep sedation should be considered a viable option for patients with advanced cancer being cared for in a palliative setting.

Continuous deep sedation (CDS) does not shorten life and should be considered a viable option for patients with advanced cancer being cared for in a palliative setting, according to a study published online ahead of print in The Lancet Oncology.1

CDS as a form of palliative care has been the subject of debate. Investigators sought to determine whether CDS shortened survival and to establish the effects of artificial hydration.

This study was part of a secondary analysis of a large multicentre prospective cohort study that recruited and followed-up patients between Sept 3, 2012, and April 30, 2014.

Patients age 20 years and older with advanced cancer who received care through the participating palliative care services were eligible. Investigators compared survival between patients who received CDS with those who did not. A propensity score-weighting method was used to control for patient characteristics, disease status, and symptom burden.

The team of Japanese investigators analyzed data from 1827 patients, 269 (15%) of which received CDS. Results showed unweighted median survival of 27 days (95% CI, 22 – 30) in the CDS group vs 26 days in the no-CDS group.

RELATED: CINV Among Topics Presented at Palliative Care Symposium

Following propensity-score weighting, median survival for those in the CDS group was 22 days for patients receiving CDS vs 26 days for patients without CDS (95% CI, 0.87 – 1.17; log-rank P = .91). Volume of artificial hydration had no effect on the association between sedation and survival.

Reference

  1. Maeda I, Morita T, Yamaguchi T, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study [published online ahead of print November 20, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00401-5.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs